{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-129415","form_type":"8-K","ticker":null,"cik":"0001305253","company_name":"Eiger BioPharmaceuticals, Inc.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.782871+00:00","generated_at":"2026-06-03T00:04:43.615955+00:00","sec_items":["5.02","7.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Eiger BioPharma CFO resigns; appoints CRO amid Chapter 11 bankruptcy","bullets":["CFO William G. Kachioff resigned effective April 29, 2024, as company restructures under Chapter 11.","Board appointed Douglas Staut (Alvarez & Marsal) as Chief Restructuring Officer effective April 19, 2024.","Company in Chapter 11 bankruptcy (Case 24-80040); relying on A&M for financial and accounting functions.","Company warns trading in its securities is highly speculative and may result in total loss for holders."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-129415","json":"https://secwatch.observer/filing/0001193125-24-129415.json","markdown":"https://secwatch.observer/filing/0001193125-24-129415.md","text":"https://secwatch.observer/filing/0001193125-24-129415.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1305253/000119312524129415/0001193125-24-129415-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1305253/000119312524129415/d833509d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:04:43.615955+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8f3f0f346a","claim":"William G. Kachioff resigned as Chief Financial Officer at Eiger BioPharmaceuticals, Inc..","evidence_excerpt":"On April 26, 2024, William G. Kachioff notified Eiger BioPharmaceuticals, Inc. (the “ Company ”) of his resignation as the Company’s Chief Financial Officer, to be effective April 29, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1305253/000119312524129415/0001193125-24-129415-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}